Determining whether to purchase Protara Therapeutics stock requires assessing your risk tolerance regarding clinical-stage biotechnology equities. Investors attracted to the stock often point to its promising oncology and rare disease pipeline developments, regulatory fast-track designations, and adequate clinical funding horizons. However, because biotech firms face binary clinical trial outcomes and regulatory approval hurdles, conservative investors typically balance potential upside against high sector risks.